These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22458755)

  • 1. Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas.
    El Khoury AC; Wallace C; Klimack WK; Razavi H
    J Med Econ; 2012; 15(5):887-96. PubMed ID: 22458755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden of hepatitis C-associated diseases in the United States.
    El Khoury AC; Klimack WK; Wallace C; Razavi H
    J Viral Hepat; 2012 Mar; 19(3):153-60. PubMed ID: 22329369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study.
    Wong WWL; Haines A; Bremner KE; Yao Z; Calzavara A; Mitsakakis N; Kwong JC; Sander B; Thein HH; Krahn MD
    CMAJ Open; 2021; 9(1):E167-E174. PubMed ID: 33688024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resource use and cost of hepatitis C-related care.
    Nevens F; Colle I; Michielsen P; Robaeys G; Moreno C; Caekelbergh K; Lamotte M; Wyffels V
    Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1191-8. PubMed ID: 22836284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements.
    Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma
    J Gastroenterol Hepatol; 2010 Apr; 25(4):657-63. PubMed ID: 20492323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients.
    Planas R; Ballesté B; Alvarez MA; Rivera M; Montoliu S; Galeras JA; Santos J; Coll S; Morillas RM; Solà R
    J Hepatol; 2004 May; 40(5):823-30. PubMed ID: 15094231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis.
    Bozorgzadeh A; Orloff M; Abt P; Tsoulfas G; Younan D; Kashyap R; Jain A; Mantry P; Maliakkal B; Khorana A; Schwartz S
    Liver Transpl; 2007 Jun; 13(6):807-13. PubMed ID: 17539001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the treatment of hepatitis C.
    Lawrence SP
    Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C.
    Buti M; San Miguel R; Brosa M; Cabasés JM; Medina M; Angel Casado M; Fosbrook L; Esteban R
    J Hepatol; 2005 May; 42(5):639-45. PubMed ID: 15826711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.
    Lin OS; Keeffe EB; Sanders GD; Owens DK
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1159-72. PubMed ID: 15153169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan.
    Chen DS
    Princess Takamatsu Symp; 1995; 25():27-32. PubMed ID: 8875606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic burden of HCV-induced diseases in Italy. A probabilistic cost of illness model.
    Marcellusi A; Viti R; Capone A; Mennini FS
    Eur Rev Med Pharmacol Sci; 2015; 19(9):1610-20. PubMed ID: 26004601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C and hepatitis B-related mortality in Spain.
    García-Fulgueiras A; García-Pina R; Morant C; García-Ortuzar V; Génova R; Alvarez E
    Eur J Gastroenterol Hepatol; 2009 Aug; 21(8):895-901. PubMed ID: 19357523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus.
    Singal AG; Volk ML; Jensen D; Di Bisceglie AM; Schoenfeld PS
    Clin Gastroenterol Hepatol; 2010 Mar; 8(3):280-8, 288.e1. PubMed ID: 19948249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis.
    Pekow JR; Bhan AK; Zheng H; Chung RT
    Cancer; 2007 Jun; 109(12):2490-6. PubMed ID: 17487861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutritional guidelines for persons infected with the hepatitis C virus: a review of the literature.
    Wendland BE
    Can J Diet Pract Res; 2001; 62(1):7-15. PubMed ID: 11518551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
    Lee KK; Wu DB; Chow PY; Lee VW; Li H
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of utilities for chronic hepatitis C from SF-36 scores.
    Thein HH; Krahn M; Kaldor JM; Dore GJ
    Am J Gastroenterol; 2005 Mar; 100(3):643-51. PubMed ID: 15743364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.